Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 25, 2025 13:14 ET | Source: AVACTA GROUP PLC

Avacta presents first preclinical data from dual payload pre|CISION® medicines at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets

LONDON and PHILADELPHIA, Oct. 25, 2025 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, ‘Avacta’, ‘the Company’), a clinical stage biopharmaceutical company developing pre|CISION®, a...
October 19, 2025 10:00 ET | Source: AVACTA GROUP PLC

Avacta Therapeutics Presents Compelling Phase 1a Data for Faridoxorubicin and the pre|CISION® Platform at the European Society of Medical Oncology Annual Congress

Avacta Therapeutics announces further development updates in the Phase 1a clinical trial with its lead program, faridoxorubicin (FAP-Dox, AVA6000).
October 13, 2025 12:00 ET | Source: AVACTA GROUP PLC

Avacta to Present First Dual Payload pre|CISION® Medicines Data at the 2025 EORTC-NCI-AACR International Conference on Molecular Targets Symposium

LONDON and PHILADELPHIA, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, ‘Avacta’, ‘the Company’), a clinical stage biopharmaceutical company developing pre|CISION®, a unique...
July 30, 2025 07:00 ET | Source: AVACTA GROUP PLC

Avacta to Present New FAP Dox (AVA6000) Data at the European Society for Medical Oncology (ESMO) Congress

LONDON and PHILADELPHIA, July 30, 2025 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, ‘the Company’), a life sciences company developing innovative, targeted oncology drugs, today announces...
July 01, 2025 07:00 ET | Source: AVACTA GROUP PLC

Avacta Appoints David Liebowitz, M.D., Ph.D. as Chief Medical Officer and Yulii Bogatyrenko as Advisor in Business Development

LONDON and PHILADELPHIA, July 01, 2025 (GLOBE NEWSWIRE) -- Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs, today announces the appointment of...
May 28, 2025 07:00 ET | Source: AVACTA GROUP PLC

Avacta Therapeutics Announces Appointments of Industry Veterans to Board of Directors

LONDON and PHILADELPHIA, May 28, 2025 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT), a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful...
April 28, 2025 07:01 ET | Source: AVACTA GROUP PLC

Avacta Therapeutics Presents Data from Lead pre|CISION® Candidate FAP-Dox (AVA6000) at the 2025 AACR Annual Meeting

Compelling Phase 1 safety and efficacy data for FAP-Dox (AVA6000) with preliminary evidence of efficacy in salivary gland cancers and no severe cardiac toxicity Progression free survival...
April 28, 2025 07:00 ET | Source: AVACTA GROUP PLC

Avacta Therapeutics Presents Preclinical and Translational Data from pre|CISION® Platform Candidates at 2025 AACR Annual Meeting

LONDON and PHILADELPHIA, April 28, 2025 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT), a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful...
March 31, 2025 07:00 ET | Source: AVACTA GROUP PLC

Avacta Provides Business Update for the First Quarter of 2025 Outlining Progress Against Strategic Objectives

AVA6000 Phase 1b expansion cohorts enrolling with data targeted for later in 2025 AVA6103 IND-enabling studies underway with a Phase 1 trial anticipated to begin in the first quarter of 2026 ...
March 26, 2025 07:00 ET | Source: AVACTA GROUP PLC

Avacta Therapeutics Announces Presentations at 2025 AACR Annual Meeting

LONDON and PHILADELPHIA, March 26, 2025 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT), a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful...